24,900 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Bayesian Capital Management LP

Bayesian Capital Management LP acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 24,900 shares of the company's stock, valued at approximately $2,142,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. lifted its holdings in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after acquiring an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock worth $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its position in Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after purchasing an additional 30,420 shares during the period. Versant Capital Management Inc bought a new position in Novo Nordisk A/S during the 4th quarter worth $86,000. Finally, Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter worth $4,066,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 4.0 %

Shares of NYSE NVO traded down $2.80 during mid-day trading on Tuesday, hitting $66.32. 10,488,030 shares of the company traded hands, compared to its average volume of 6,255,246. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The stock has a market capitalization of $297.63 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 0.90 and a beta of 0.65. The business has a 50 day moving average of $70.60 and a two-hundred day moving average of $87.08.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is 49.54%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NVO. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.